Migraine treatment advances!
The understanding of migraine pathophysiology has advanced in recent decades.
New treatments targeting calcitonin gene-related peptide, its receptor, and serotonin 5HT1F receptors have demonstrated efficacy for treating migraine in many patients in real-world and clinical trial data; however, there is still a significant proportion of patients who do not respond to these new therapies.
There are positive Phase 2 data for a monoclonal antibody targeting the pituitary adenylate cyclase activating polypeptide. Preclinical studies suggest a role for receptor component protein, adrenomedullin, and amylin peptides as well as KATP and transient receptor potential ion channels and neuronal nitric oxide synthase in migraine, which may be suitable targets for the development of new treatments.
Elucidating the exact pathways and mechanisms by which these targets may influence migraine management may help identify other therapeutic targets that may bypass adverse effects.
Variability in response to treatment may reflect differences in migraine pathophysiology reflected by differing symptoms between patients, suggesting interindividual heterogeneity in migraine biology.
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(25)00205-9
